Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin
Public ClinicalTrials.gov record NCT01309932. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2B, Randomized Study to Evaluate the Safety and Efficacy of Pegylated Interferon Lambda (BMS-914143) Administered With Ribavirin Plus a Single Direct Antiviral Agent (BMS-790052 or BMS-650032) Versus Pegasys Administered With Ribavirin (Part A) and of Pegylated Interferon Lambda (BMS-914143) Administered With or Without Ribavirin Plus 2 Direct Antiviral Agents (BMS-790052 and BMS-650032) (Part B) in Chronic Hepatitis C Genotype-1 Treatment naïve Subjects
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine if combination therapy with Pegylated Interferon Lambda (BMS-914143) plus Ribavirin (RBV) with a single direct antiviral agent (BMS-790052 or BMS-650032) for 24 weeks is effective and safe for treatment of Chronic Hepatitis C (CHC) compared to current standard therapy with Pegylated Interferon Alpha-2a plus RBV for 48 weeks.
Study identification
- NCT ID
- NCT01309932
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 165 participants
Conditions and interventions
Conditions
Interventions
- Pegylated Interferon Lambda (pegIFNλ) Biological
- BMS-790052 (NS5A Inhibitor) Drug
- Ribavirin (RBV) Drug
- BMS-650032 (NS3 Protease Inhibitor) Drug
- Pegylated Interferon Alfa-2a (pegIFNα-2a) Biological
- Placebo (PBO) for BMS-650032 (Placebo for NS3 Protease Inhibitor) Drug
- Placebo (PBO) for BMS-790052 (Placebo for NS5A Inhibitor) Drug
- Placebo for Ribavirin (RBV) Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 28, 2011
- Primary completion
- Jun 30, 2014
- Completion
- Aug 31, 2014
- Last update posted
- Oct 8, 2015
2011 – 2014
United States locations
- U.S. sites
- 13
- U.S. states
- 11
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic Hospital | Phoenix | Arizona | 85054 | — |
| Desert Medical Group Inc. | Palm Springs | California | 92262 | — |
| University Of Colorado Denver And Hospital | Aurora | Colorado | 80045 | — |
| Yale University School Of Medicine | New Haven | Connecticut | 06510 | — |
| Johns Hopkins University | Lutherville | Maryland | 21093 | — |
| Henry Ford Health System | Detroit | Michigan | 48202 | — |
| Bristol-Myers Squibb/David E. Bernstein, Md | Manhasset | New York | 11030 | — |
| Carolinas Medical Center | Charlotte | North Carolina | 28203 | — |
| Carolinas Center For Liver Disease | Statesville | North Carolina | 28677 | — |
| St. Luke'S Episcopal Hospital - Baylor College Of Medicine | Houston | Texas | 77030 | — |
| Texas Liver Institute | San Antonio | Texas | 78215 | — |
| Metropolitan Research | Fairfax | Virginia | 22031 | — |
| Virginia Mason Medical Center | Seattle | Washington | 98101 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 27 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01309932, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 8, 2015 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01309932 live on ClinicalTrials.gov.